Effect of tezepelumab on the proportion of exacerbation-free patients with severe, uncontrolled asthma in NAVIGATOR Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Prediction of the risk of future exacerbations in patients with severe persistent allergic asthma Source: Annual Congress 2005 - Severe asthma: perception and management Year: 2005
Risk factors for severe exacerbations in a real-life population of adults with severe refractory asthma Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017
Is anemia associated with readmission risk in severe acute exacerbation of COPD: Preliminary results from a naturalistic cohort Source: Virtual Congress 2020 – Clinical data and COPD management Year: 2020
Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017
Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009
Predictors of low risk of asthma exacerbation during pregnancyA prospective study of 1,283 pregnancies Source: International Congress 2017 – Management of asthma in different situations Year: 2017
Incidence and risk factors of pediatric asthma exacerbations in a multinational, multidatabase cohort study Source: International Congress 2018 – New developments in paediatric asthma Year: 2018
Evaluating the efficacy of omalizumab in severe persistent asthma patients Source: International Congress 2017 – Evolution or revolution in the treatment of asthma and allergies Year: 2017
Severe outcomes of COVID-19 among patients with COPD and asthma Source: ERJ Open Res, 7 (1) 00594-2020; 10.1183/23120541.00594-2020 Year: 2021
Incidence and risk factors of frequent asthma exacerbations in a multinational, multidatabase cohort study Source: International Congress 2019 – Epidemiology of airway diseases in primary care Year: 2019
Patient characteristics, biomarkers and exacerbation risk in severe, uncontrolled asthma Source: Eur Respir J, 58 (6) 2100413; 10.1183/13993003.00413-2021 Year: 2021
Omalizumab is effective in patients with severe persistent allergic asthma in a real-life setting irrespective of age Source: Annual Congress 2009 - Towards improving asthma control Year: 2009
Effect of asthma exacerbation during pregnancy in women with asthma: a population-based cohort study Source: Eur Respir J, 55 (2) 1901335; 10.1183/13993003.01335-2019 Year: 2020
Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012
Which are the factors and causes that lead to omalizumab withdrawal in severe asthma patients? Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
Characteristics of asthma patients with frequent exacerbations – an observational study in Sweden Source: International Congress 2017 – Primary care management of asthma and self-management of respiratory disease Year: 2017
Effect of roflumilast in patients with severe COPD and a history of hospitalisation Source: Eur Respir J, 50 (1) 1700158; 10.1183/13993003.00158-2017 Year: 2017
Effect of asthma and asthma medication on the prognosis of patients with COVID-19 Source: Eur Respir J, 57 (3) 2002226; 10.1183/13993003.02226-2020 Year: 2021
Analysis of two-year treatment with omalizumab patients with severe asthma in real clinical practice Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019